Arcutis Biotherapeutics Statistics
Share Statistics
Arcutis Biotherapeutics has 117.05M shares outstanding. The number of shares has increased by 1.8% in one year.
| Shares Outstanding | 117.05M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.13% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 102.98M |
| Failed to Deliver (FTD) Shares | 295 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 23.11M, so 19.75% of the outstanding shares have been sold short.
| Short Interest | 23.11M |
| Short % of Shares Out | 19.75% |
| Short % of Float | 22.44% |
| Short Ratio (days to cover) | 11.87 |
Valuation Ratios
The PE ratio is -0.85 and the forward PE ratio is -10.46.
| PE Ratio | -0.85 |
| Forward PE | -10.46 |
| PS Ratio | 3.76 |
| Forward PS | 3.8 |
| PB Ratio | 2.52 |
| P/FCF Ratio | -0.9 |
| PEG Ratio | n/a |
Enterprise Valuation
Arcutis Biotherapeutics Inc. has an Enterprise Value (EV) of 340.45M.
| EV / Earnings | -1.3 |
| EV / Sales | 5.71 |
| EV / EBITDA | -1.5 |
| EV / EBIT | -1.41 |
| EV / FCF | -1.38 |
Financial Position
The company has a current ratio of 7.08, with a Debt / Equity ratio of 2.28.
| Current Ratio | 7.08 |
| Quick Ratio | 6.8 |
| Debt / Equity | 2.28 |
| Total Debt / Capitalization | 69.47 |
| Cash Flow / Debt | -1.22 |
| Interest Coverage | -8.11 |
Financial Efficiency
Return on equity (ROE) is -2.96% and return on capital (ROIC) is -82.83%.
| Return on Equity (ROE) | -2.96% |
| Return on Assets (ROA) | -0.77% |
| Return on Capital (ROIC) | -82.83% |
| Revenue Per Employee | 201.37K |
| Profits Per Employee | -885.61K |
| Employee Count | 296 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.38 |
Taxes
| Income Tax | 3.11M |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by 282.42% in the last 52 weeks. The beta is 1.19, so Arcutis Biotherapeutics 's price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | 282.42% |
| 50-Day Moving Average | 12.26 |
| 200-Day Moving Average | 10.14 |
| Relative Strength Index (RSI) | 46.96 |
| Average Volume (20 Days) | 2.12M |
Income Statement
In the last 12 months, Arcutis Biotherapeutics had revenue of 59.61M and earned -262.14M in profits. Earnings per share was -3.78.
| Revenue | 59.61M |
| Gross Profit | 54.62M |
| Operating Income | -241.10M |
| Net Income | -262.14M |
| EBITDA | -227.43M |
| EBIT | -241.10M |
| Earnings Per Share (EPS) | -3.78 |
Balance Sheet
The company has 88.40M in cash and 205.92M in debt, giving a net cash position of -117.52M.
| Cash & Cash Equivalents | 88.40M |
| Total Debt | 205.92M |
| Net Cash | -117.52M |
| Retained Earnings | -981.90M |
| Total Assets | 437.35M |
| Working Capital | 251.29M |
Cash Flow
In the last 12 months, operating cash flow was -247.06M and capital expenditures -428.00K, giving a free cash flow of -247.49M.
| Operating Cash Flow | -247.06M |
| Capital Expenditures | -428.00K |
| Free Cash Flow | -247.49M |
| FCF Per Share | -3.57 |
Margins
Gross margin is 91.63%, with operating and profit margins of -404.49% and -439.79%.
| Gross Margin | 91.63% |
| Operating Margin | -404.49% |
| Pretax Margin | -434.57% |
| Profit Margin | -439.79% |
| EBITDA Margin | -381.56% |
| EBIT Margin | -404.49% |
| FCF Margin | -415.2% |
Dividends & Yields
ARQT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -28.49% |
| FCF Yield | -15.93% |
Analyst Forecast
The average price target for ARQT is $19, which is 43.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $19 |
| Price Target Difference | 43.2% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -0.07 |
| Piotroski F-Score | 3 |